Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LCTX$1.04-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| NET LOSS | $(21,479) | $(26,353) |
| Other comprehensive loss, net of tax: | ||
| Foreign currency translation adjustment | 353 | 1,790 |
| Unrealized gain (loss) on marketable debt securities | 150 | (150) |
| COMPREHENSIVE LOSS | (20,976) | (24,713) |
| Less: Comprehensive (income) loss attributable to noncontrolling interest | (7) | 80 |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE COMMON SHAREHOLDERS | $(20,983) | $(24,633) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.